Wednesday, November 04, 2009 8:34:41 AM
8:03a ET November 4, 2009 (GlobeNewswire)
XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced the grant of its first European Patent related to the XOMA 052 program. Granted by the European Patent Office, the patent covers XOMA's interleukin-1 beta (IL-1 beta) antibody XOMA 052, as well as nucleic acids, expression vectors and production cell lines for the manufacture of XOMA 052. The patent provides exclusivity in Europe into 2026.
IL-1 beta is a pro-inflammatory cytokine involved in the development of Type 2 diabetes, cardiovascular disease, rheumatoid arthritis, gout and other diseases. By binding to IL-1 beta, XOMA 052 inhibits the activation of the IL-1 receptor, thereby preventing the cellular signaling events that produce inflammation. Earlier this year, XOMA completed successful Phase 1 trials of XOMA 052 in Type 2 diabetes patients, and has initiated its Phase 2 clinical development program in Type 2 diabetes and cardiovascular disease.
"This new patent is XOMA's first European patent providing exclusivity for XOMA 052 and complements our two U.S. Patents, which issued earlier this year," said Steven Engle, XOMA Chairman and Chief Executive Officer.
Recent XOMA News
- XOMA Royalty to Present at Upcoming Investor Conferences in September • GlobeNewswire Inc. • 09/04/2024 11:30:00 AM
- XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities • GlobeNewswire Inc. • 08/13/2024 11:30:00 AM
- XOMA Declares Quarterly Preferred Stock Dividends • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher • GlobeNewswire Inc. • 06/12/2024 11:30:00 AM
- XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2% • GlobeNewswire Inc. • 04/30/2024 11:30:00 AM
- XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) • GlobeNewswire Inc. • 04/25/2024 11:30:00 AM
- Actym Therapeutics Appoints Thomas Smart as CEO • PR Newswire (US) • 04/24/2024 01:00:00 PM
- XOMA Corporation Announces Closing of Tender Offer • GlobeNewswire Inc. • 04/03/2024 01:00:00 PM
- XOMA Declares Quarterly Preferred Stock Dividends • GlobeNewswire Inc. • 03/21/2024 11:30:00 AM
- XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc. • GlobeNewswire Inc. • 03/19/2024 08:05:00 PM
- XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value • GlobeNewswire Inc. • 03/08/2024 12:30:00 PM
- XOMA to Present at Upcoming Investor Conferences in March • GlobeNewswire Inc. • 02/28/2024 12:30:00 PM
- XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right • GlobeNewswire Inc. • 02/16/2024 01:00:00 PM
- XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition • GlobeNewswire Inc. • 01/18/2024 01:30:00 PM
- Xoma to Make $1 Million Milestone Payment to LadRx After FDA Accepts Zevra Application for Arimoclomol • Dow Jones News • 01/11/2024 09:50:00 PM
- FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx • GlobeNewswire Inc. • 01/11/2024 09:05:00 PM
- XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors • GlobeNewswire Inc. • 01/08/2024 12:30:00 PM
- XOMA Announces Stock Repurchase Program of up to $50 Million • GlobeNewswire Inc. • 01/02/2024 12:30:00 PM
- XOMA Declares Quarterly Preferred Stock Dividends • GlobeNewswire Inc. • 12/20/2023 12:30:00 PM
- XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties • GlobeNewswire Inc. • 12/19/2023 12:30:00 PM
- XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value • GlobeNewswire Inc. • 11/07/2023 12:30:00 PM
- XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG) • GlobeNewswire Inc. • 10/31/2023 11:30:00 AM
- XOMA Declares Quarterly Preferred Stock Dividends • GlobeNewswire Inc. • 09/25/2023 11:30:00 AM
Simple Stock Loans Announces Unique Solutions For Investors Looking for Alternative Liquidity Amidst Recent Small Cap Rally Sep 6, 2024 9:30 AM
Reliant Coffee Debuts at #271 on the Inc. 5000 List of Fastest Growing Companies - Coffee Service Industry Disruptor Brews Up Exponential Growth Sep 5, 2024 11:51 AM
VAYK Confirms Receiving Revenue from First Airbnb Property with 1.4 Million Annual Revenue Goal • VAYK • Sep 4, 2024 9:34 AM
Mawson Finland Limited Expands Known Mineralized Zones at Rajapalot: New Lens Intercepts 21.75 m at 5.25 g/t Gold & 515 ppm Cobalt • MFL • Sep 4, 2024 9:02 AM
Integrated Ventures Acquires 51% Stake In GetTrim.Com (TM), Telemedicine Platform With Focus On Expansion Into Booming GLP-1 Powered Weight Loss Market • INTV • Sep 4, 2024 8:45 AM
Avant Technologies Announces Strategic Review Process Intended to Maximize Shareholder Value • AVAI • Sep 4, 2024 8:00 AM